Please login to the form below

Not currently logged in
Email:
Password:

Delay for inhaled hypertension treatment

United Therapeutics has announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin

United Therapeutics Corp today announced it is likely to face regulatory delays for the inhaled version of its hypertension drug Remodulin because of Food and Drug Administration (FDA) concerns over patient instructions.

The company had expected a decision from the FDA by April 30, but will likely face delays because of questions over instructions for using the nebuliser that delivers the drug.

United Therapeutics is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. The company already sells the drug as an injection called Remodulin. The inhaled version is called Tyvaso.

"Following our most recent discussion with the FDA, we have agreed to conduct human factors testing to validate that the revised instructions for use (IFU) results in the proper use of the device by a naive user," said President and Chief Operating Officer Roger Jeffs, in a statement. "This relatively small study in normal subjects will test the new IFU in its ability to guide patients to accomplish such tasks as proper device assembly, drug administration, disassembly and cleaning, among other things."

Shares of United Therapeutics sank $2 (or 3 per cent) to $66.28 in pre-market activity.

16th March 2009

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics